Shwachman-Diamond syndrome (SDS) is a rare hereditary disorder characterized by pancreatic exocrine insufficiency, bone marrow dysfunction and skeletal changes. Recently, the cause of SDS was identified as mutations of Shwachman-BodianDiamond syndrome gene (SBDS) and most mutations are caused by gene conversion between SBDS and its highly homologous pseudogene. Clinical variations especially in skeletal and bone marrow abnormalities are well known in this syndrome. To study the relationship between SBDS mutation and its clinical features, we analyzed 9 Japanese patients including one sibling and detected the three different SBDS mutations in 7 patients: a mutation that disrupts the donor splice site of intron 2, deletes 8bp of the exon 2 and produces premature termination (258+2 T > C), a dinucleotide change that replaces a lysine at 62nd amino acid to a termination codon (183-184 TA > CT), and a 4-bp deletion that causes premature termination by frameshift (292-295 delAAAG). The 5 patients represent compound heterozygotes of the 258+2 T > C and 183-184 TA > CT mutations. One patient is a compound heterozygote of the 258+2 T > C and 292-295 delAAAG mutations, and in the remaining one case only a 258+2 T > C mutation could be detected. Thus, the 258+2 T > C and 183-184 TA > CT mutations are prevalent among Japanese patients. No mutations were found in two cases, despite the clinical features. Of the 7 patients with SBDS mutations, persistent hematologic abnormalities and skeletal changes were not observed in 3 and 2 patients, respectively. Notably, clinical variations are present even among the patients with the identical genotype: compound heterozygotes of the 258+2 T >
Shwachman-Diamond syndrome (SDS) is characterized by pancreatic exocrine insufficiency, bone marrow dysfunction and skeletal changes. The incidence of this syndrome has been estimated to range from approximately 1/100,000 to 1/200,000, and the ratio of males to females is 1.8 to 2.4 (Dror and Freedman 2002; Smith 2002) . Studies of family pedigrees have suggested an autosomal recessive mode of inheritance for this disease (Dror and Freedman 2002) .
SDS manifests in various clinical features, including failure to thrive, neutropenia, and reduced response for pancreatic stimulation test.
Other clinical features, such as skeletal abnormalities, anemia, and bone marrow hypoplasia, are not always observed (Dror and Freedman 2002; Smith 2002) . Approximately 25% of cases have been reported to develop aplastic anemia, myelodysplastic syndrome or leukemia (Dror and Freedman 2002; Smith 2002; Mitsui et al. 2004) .
Cytogenetic studies of bone marrow aspirates from SDS patients who developed myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) more frequently showed structural abnormalities of chromosome 7q as compared to MDS without SDS (Smith et al. 1995; Smith et al. C and 183-184 TA > CT mutations. Further study will be required to explain the clinical heterogeneity.
Shwachman-Diamond syndrome; SBDS; mutations; clinical heterogeneity. 258+2T > C  258+2T > C  258+2T > C  allele 2 292-295delAAAG ND 183-184TA > CT 1996). The SDS locus was mapped to a 1.9-cM interval at 7q11 and a disease-causing gene was identified as the Shwachman-Bodian-Diamond syndrome gene (SBDS) (Goobie et al. 2001; Popovic et al. 2002; Boocock et al. 2003) . Most mutations detected in the patients are introduced by gene conversion between SBDS and its highly homologous pseudogene (SBDSP). Even after the disease-causing gene was identified, there are no available data in the relationship between clinical heterogeneity in SDS and SBDS mutations. We analyzed SBDS in 9 Japanese patients to investigate the molecular basis of Japanese SDS patients and the genotype-phenotype relationship.
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MATERIALS AND METHODS
Patients
The diagnostic criterion was the presence of both pancreatic exocrine insufficiency and hematologic abnormalities with or without skeletal changes (Dror and Freedman 2002) . Hematologic abnormalities were defined as transitory or persistent neutropenia with or without anemia and thrombocytopenia. Skeletal changes were defined as any one of metaphyseal dysostosis, narrow thoracic cage or flared anterior end of the ribs (Taybi et al. 1969) . Most patients showed failure to thrive below -2.0 SD in height. All patients received diagnosis of SDS by pediatricians before 8 years of age.
Representative clinical data of all patients are shown in Table 1 . All patients except cases 4 and 5 were unrelated. Case 1 developed de novo AML at 18 years old and underwent successful unrelated bone marrow transplantation three years prior to the current study (Mitsui et al. 2004) . Case 2 had an affected elder brother who died of sepsis at 5 years of age. Cases 2 and 3 both developed AML following MDS and subsequently died at 7 and 30 years of age, respectively. Case 3 was also complicated with insulin dependent diabetes mellitus at 16 years of age. Case 4 showed typical symptoms of SDS. -3.5 S.D.
was an elder sister of case 4. She had exocrine pancreatic insufficiency in addition to a transposition of the great arteries but showed no hematologic and skeletal abnormalities. Case 6 demonstrated contracted kidneys in a computerized axial tomography scan, and showed moderate renal hypofunction on scintigram. Her renal biopsy revealed focal glomerular obsolescence. She showed transient neutropenia (966/μ l) at 2 years 3 months of age, but otherwise had no hematologic and skeletal abnormalities. Case 7 had neutropenia during his early childhood, but showed neither persistent neutropenia nor skeletal abnormalities. Case 8 had typical features of SDS with skeletal abnormalities. Case 9 was an infant presenting with neutropenia but had no skeletal abnormalities. Chromosomal analyses were performed in 7 patients and only case 9 showed an abnormal karyotype; 46, XY, t (4,5) (p15.2; q11.2).
Mutation Analysis
The Ethics Committee of the Yamagata University School of Medicine approved this study. With written informed consent from the patients and their families, peripheral blood specimens or bone marrow aspirates were used for genomic DNA extraction.
Sequences of mRNA and genomic DNA of SBDS and SBDSP were obtained from a public database (GenBank, NM_016038, NT_086711, NR_001588). All coding regions of SBDS including exon-intron boundaries were amplified by PCR using the set of primers and annealing temperatures listed in Table 2 . All primers were set in a non-coding region specific for SBDS other than SBDSP based on the genomic information. Genomic DNA (0.2 -1.0 μ g) was amplified with each 0.2 μ M of primer pairs, 0.2 mM with each dNTP 2.5 U Taq DNA polymerase (Takara Bio, Otsu) and the buffer contained 10 mM Tris-HCl, pH 8.3, 50 mM KCl, and 1.5 mM MgCl 2 in a final volume of 50 μ l. The samples were heated for 3 minutes at 94°C and then 30 cycles (94°C for 30 seconds, annealing temperatures as listed in Table 2 for 60 seconds, and 72°C for 60 seconds), followed by 72°C for 5 minutes using a DNA thermal cycler (Gene Amp, PCR system model 9700; Perkin Elmer, Foster City, CA, USA). PCR products were purified and sequenced directly using the ABI PRISM Genomic Analyzer 310 (Applied Biosystem, Foster City, CA, USA). To confirm the mutations, PCR fragments were subcloned using T-vector (pBluescript, Stratagene, La Jolla, CA, USA) with a DNA Ligation Kit (Takara Bio) according to the manufacturer's instructions. Obtained plasmid vectors were amplified with E.coli JM109 Competent Cells (Takara Bio), and six clones of each sample were sequenced. Table 1 , mutations of SBDS were detected in 7 cases and all except case 2 were compound heterozygotes for the mutations. In case 2, the mutation was not identified on an allele inherited from his mother. The 258+2 T > C and 183-184 TA > CT mutations in exon 2 were detected in 7 and 5 patients, respectively. Case 1 was a compound heterozygote for the 258+2 T > C and 292-295 delAAAG mutations inherited from his father and mother, respectively. Cases 4 and 5, sibling cases, shared the same SBDS mutations. No mutation in the coding regions of SBDS was found in cases 6 and 7.
RESULTS
As shown in
The mutation 258+2 T > C denotes that a T is changed to a C at the second nucleotide in the beginning of intron 2 (Fig. 1) . Boocock et al. (2003) described a 8-bp deletion in the end of exon 2 detected by RT-PCR analysis among the patients with this mutation. This is consistent with use of an upstream cryptic splice donor site at position 251-252. This leads to a frameshift and results in a premature termination codon at the following third amino acid: 84CfsX3. The mutation 183-184 TA > CT denotes that TA is substituted for CT at nucleotides 183-184. This is predicted to introduce an in-frame stop codon at 62nd amino acid lysine: K62X. The mutation 292-295 delAAAG denotes that a 4bp deletion at nucleotides 292-295 causes premature termination by frameshift at the following twentieth amino acid: E99fsX20.
DISCUSSION
We analyzed 9 Japanese patients with SDS and found 3 different mutations of SBDS in 7 patients. We confirmed that the 258+2 T > C and 183-184 TA > CT mutations are as common among Japanese patients as in patients from other nations and found that the clinical phenotypes are variable even among patients with an identical genotype.
In 2003, Boocock et al. (2003) identified SBDS, which is located at 7q11 and consists of 5 exons. SBDS has a 1.6 kb transcript and encodes a predicted protein of 28.8kDa with 250 amino acids. The duplicon of this gene locates 5.8 Mb distally and contains an unprocessed pseudogene designated as SBDSP. The nucleotide sequences of SBDSP are 97% homologous to SBDS. Boocock et al. (2003) reported that conversion mutations between SBDS and SBDSP were detected in about 90% of patients with SDS. They designated 2 common mutations: the 258+2 T > C and 183-184 TA > CT mutations, and found 79 families were compound heterozygotes for these two mutations in 141 SDS families. Recently, Nakashima et al. (2004) analyzed SBDS in 7 SDS Japanese patients including one sibling and found that 5 patients had the 258+2 T > C mutation and 2 of them had the 183-184 TA > CT mutation on another allele. As shown in Table 3 , the 258+2 T > C and 183-184 TA > CT mutations are prevalent among Japanese patients similar to patients of European ancestry (Boocock et al. 2003) . We detected single nucleotide polymorphisms such as 201 A > G in the patients with these mutations. However these polymorphisms were not always accompanied by mutant alleles. Recurrent mutations are the most likely explanation for this prevalence rather than founder mutations. All Japanese cases detected as having the mutations were compound heterozygous for the mutations. A recent decline in consanguineous marriages in Japan may have contributed in part to the absence of homozygous patients (Saito 1988 ). In addition, Nakashima et al. (2004) reported a novel 292-295 delAAAG mutation that is also likely introduced by gene conversion and we detected in one case, suggesting a common mutation in Japanese patients.
The 258+2 T > C mutation is predicted to disrupt the donor splice site of intron 2 (GT GC). But recent studies showed that GC can also very occasionally be a donor splice site, estimated as 0.69% among the whole set of mammalian splice sites (Burset et al. 2000) . Boocock et al. (2003) confirmed a deletion of 8 bp at the end of the exon 2 was recurring by RT-PCR analysis among SDS patients with 258+2 T > C. Thus the 258+2 T > C change induces a disruption of the donor splice site of GT and results in use of an upstream cryptic donor splice site at position 251-252 (GT) in SDS patients.
Gene conversion is one of the important mechanisms causing human genetic diseases. A well-known disease caused by gene conversion is 21-hydroxylase deficiency; gene conversion is confirmed in approximately 85% of the patients (Morel et al. 1989) . The presence of highly homologous, tandemly arranged genes provides an opportunity for meiotic mispairing and crossing over between sister chromatids. The incidence of 21-hydroxylase deficiency in Europe, North America and Japan ranges from 1/10,000 to 1/25,000. However, the incidence of SDS is extremely low and has been estimated to range from approximately 1/100,000 to 1/200,000. The frequency of gene conversion may be affected by the gene structure around the two loci and/or the size and similarity between the homologous duplicons. Our present study demonstrated that hematologic abnormalities are variable even among the patients with identical genotypes. We found that 5 patients including one sibling (cases 3, 4, 5, 8 and 9) were compound heterozygotes for the 258+2 T > C and 183-184 TA > CT mutations. Among these 5 patients, case 5 did not show any hematologic or skeletal abnormalities and case 9 had no skeletal abnormalities. Prior to the development of MDS or AML, cases 1 and 3 also did not show persistent hematologic abnormalities. It is interesting to note that cases 4 and 5 were siblings with same genotype, but they showed different clinical manifestations. Discordance of skeletal features in SDS had been reported previously (Mack et al. 1996; Ginzberg et al. 1999; Dror and Freedman 2002; Smith 2002) and Mäkitie et al. (2004) recently demonstrated that the skeletal changes were variable even among patients with identical genotypes. Mutations identified to date in affected Japanese individuals from 14 families. These are integrated data of Nakashima et al. 2004 and this report.
SBDS encodes a member of a highly conserved protein family that exists from archaea to vertebrates and plants. SBDS transcripts are widely expressed including in the kidney, skeletal muscle, lung, liver, heart, brain, and pancreas in humans. The orthologs suggest a function associated with RNA metabolism, but its biological nature has not been fully determined yet (Boocock et al. 2003) . Many biological steps are likely involved in the pathologic process of SDS. Other genetic and/or epigenetic factors may modify the pathogenesis as speculated from the predominant incidence in males, and may contribute to the clinical heterogeneity of SDS.
We could not detect any mutations in the coding regions of SBDS in cases 6 and 7. Previous papers also reported that SBDS mutation was not detected in 20-30% of patients (Boocock et al. 2003; Nakashima et al. 2004) . Cases 6 and 7 did not have persistent hematologic abnormalities except for transitory neutropenia and did not have any skeletal abnormalities. They may have a mutation in the non-coding regions of SBDS. We can also consider that they may have a mutation of another gene affecting RNA metabolism showing SDS similar symptoms.
Further studies are required to define the function of SBDS and an association of SBDS mutation with its clinical phenotypes.
